Effect of TACE plus lenvatinib and PD-1 combination therapy on unresectable hepatocellular carcinoma
[Objective]To explore the effects of transcatheter arterial chemoembolization(TACE)plus lenvatinib and PD-1 monoclonal antibody combination therapy on the efficacy and immune function of patients with unresectable hepatocellular carcinoma.[Methods]The clinical data of 50 patients who were clinically diagnosed with advanced hepatocellular carcinoma in Xiaogan Central Hospital from August 2021 to March 2023 were retrospectively analyzed.The patients were divided into 25 cases in the observation group(treated with TACE plus lenvatinib and PD-1 monoclonal antibody,hereinafter referred to as the"triple therapy")and 25 cases in the control group(treated with TACE plus lenvatinib,hereinafter referred to as the"double therapy")according to the treatment plan.The efficacy,survival and immune function indexes of the two groups were compared.[Results]There was no statistically significant difference between the general information indexes of the two groups of patients.Univariate regression analysis showed that treatment regimen and portal vein thrombosis were associated with the prognosis of patients with hepatocellular carcinoma,and multivariate regression analysis showed that treatment regimen and portal vein thrombosis were independent influences on the prognosis of hepatocellular carcinoma.The objective response rate(ORR)of the observation group was also better than that of the control group(36％vs.16％,P＜0.001).The observation group had a stronger immunomodulatory function than the control group in patients with unresectable hepatocellular carcinoma.The median overall survival(OS)(19.80 months vs.16.10 months,P=0.035)and median progression-free survival(PFS)(10.10 months vs.6.70 months,P=0.041)were better in the observation group than in the control group.[Conclusion]The results of this study show that triple therapy has better efficacy than double therapy,prolongs the overall survival and progression-free survival of patients with unresectable hepatocellular carcinoma,has less effect on the immune function of such patients,effectively improves the prognosis of patients,and also provides a new idea as well as theoretical basis for the treatment of hepatocellular carcinoma.
万方数据
维普
